{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:57:16Z","timestamp":1790841436533,"version":"4.1.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T00:00:00Z","timestamp":1674777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Cardiac amyloidosis (CA) is primarily a restrictive cardiomyopathy in which the impairment of diastolic function is dominant. Despite this, the left ventricular ejection fraction (LVEF) may be depressed in the late stage of the disease, but it poorly predicts prognosis in the earlier phases and does not represent well the pathophysiology of CA. Many echocardiographic parameters resulted important diagnostic and prognostic tools in patients with CA. Stroke volume (SV) and myocardial contraction fraction (MCF) may be obtained both with echocardiography and cardiac magnetic resonance (MRI). They reflect many factors intrinsically related to the pathophysiology of CA and are therefore potentially associated with symptoms and prognosis in CA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To collect and summarize the current evidence on SV and MCF and their clinical and prognostic role in transthyretin (TTR-CA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and results<\/jats:title><jats:p>We performed a systematic review following the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. We searched the literature database for studies focusing on SV and MCF in patients with TTR-CA. We analysed the following databases: PUBMED, Cochrane Library, EMBASE, and Web of Science database. Fourteen studies were included in the review. Both SV and MCF have important prognostic implications and are related to mortality. Furthermore, SV is more related to symptoms than LVEF and predicts tolerability of beta-blocker therapy in TTR-CA. Finally, SV showed to be an excellent measure to suggest the presence of TTR-CA in patients with severe aortic stenosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Stroke volume and MCF are very informative parameters that should be routinely assessed during the standard echocardiographic examination of all patients with TTR-CA. They carry a prognostic role while being associated with patients\u2019 symptoms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p><jats:ext-link>https:\/\/doi.org\/10.17605\/OSF.IO\/ME7DS<\/jats:ext-link>.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2023.1085824","type":"journal-article","created":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T04:52:07Z","timestamp":1674795127000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Stroke volume and myocardial contraction fraction in transthyretin amyloidosis cardiomyopathy: A systematic review"],"prefix":"10.3389","volume":"10","author":[{"given":"Serenelli","family":"Matteo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cantone","family":"Anna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanguettoli","family":"Federico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maio","family":"Daniele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabbri","family":"Gioele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dal Passo","family":"Beatrice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavasini","family":"Rita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonet","family":"Elisabetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Passarini","family":"Giulia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapezzi","family":"Claudio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Campo","family":"Gianluca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwab127","article-title":"A national survey on prevalence of possible echocardiographic red flags of amyloid cardiomyopathy in consecutive patients undergoing routine echocardiography: study design and patients characterization\u2014the first insight from the AC-TIVE Study.","author":"Merlo","year":"2021","journal-title":"Eur J Prev Cardiol."},{"key":"B2","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1002\/ejhf.2504","article-title":"Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the AC-TIVE study, an Italian nationwide survey.","volume":"24","author":"Merlo","year":"2022","journal-title":"Eur J Heart Fail."},{"key":"B3","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1080\/07853890701842988","article-title":"Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study.","volume":"40","author":"Tanskanen","year":"2008","journal-title":"Ann Med."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018016402","article-title":"Epidemiology of AL amyloidosis: a real-world study using US claims data.","volume":"2","author":"Quock","year":"2018","journal-title":"Blood Adv."},{"key":"B5","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J."},{"key":"B6","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1182\/blood-2018-06-858951","article-title":"Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis.","volume":"133","author":"Lilleness","year":"2019","journal-title":"Blood."},{"key":"B7","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis.","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J Clin Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements.","volume":"30","author":"Kumar","year":"2012","journal-title":"J Clin Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis.","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J."},{"key":"B10","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1093\/eurheartj\/ehab507","article-title":"Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis.","volume":"43","author":"Cohen","year":"2021","journal-title":"Eur Heart J."},{"key":"B11","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.jcmg.2019.10.011","article-title":"Multiparametric echocardiography scores for the diagnosis of cardiac amyloidosis.","volume":"13","author":"Boldrini","year":"2020","journal-title":"JACC Cardiovasc Imaging."},{"key":"B12","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.jcmg.2018.02.016","article-title":"Cardiac structural and functional consequences of amyloid deposition by cardiac magnetic resonance and echocardiography and their prognostic roles.","volume":"12","author":"Knight","year":"2019","journal-title":"JACC Cardiovasc Imaging."},{"key":"B13","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/S0735-1097(02)01944-7","article-title":"Myocardial contraction fraction: a volumetric index of myocardial shortening by freehand three-dimensional echocardiography.","volume":"40","author":"King","year":"2002","journal-title":"J Am Coll Cardiol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1161\/CIRCHEARTFAILURE.109.910455","article-title":"Pressure-volume relationships in patients with transthyretin (ATTR) cardiac amyloidosis secondary to V122i mutations and wild-type transthyretin transthyretin cardiac amyloid study (TRACS).","volume":"4","author":"Bhuiyan","year":"2011","journal-title":"Circ Heart Fail."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1093\/eurheartj\/ehz905","article-title":"Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis.","volume":"41","author":"Chacko","year":"2020","journal-title":"Eur Heart J."},{"key":"B16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3109\/13506129.2014.994202","article-title":"The myocardial contraction fraction is superior to ejection fraction in predicting survival in patients with AL cardiac amyloidosis.","volume":"22","author":"Tendler","year":"2015","journal-title":"Amyloid."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2018.07.001","article-title":"Myocardial contraction fraction by M-Mode echocardiography is superior to ejection fraction in predicting mortality in transthyretin amyloidosis.","volume":"24","author":"Rubin","year":"2018","journal-title":"J Card Fail."},{"key":"B18","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/13506129.2020.1722098","article-title":"Restrictive cardiac phenotype as primary cause of impaired aerobic capacity in Afro-Caribbean patients with val122ile variant transthyretin amyloid cardiomyopathy.","volume":"27","author":"Monfort","year":"2020","journal-title":"Amyloid."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1093\/ehjci\/jew324","article-title":"Myocardial contraction fraction derived from cardiovascular magnetic resonance cine images\u2014reference values and performance in patients with heart failure and left ventricular hypertrophy.","volume":"18","author":"Arenja","year":"2017","journal-title":"Eur Heart J Cardiovasc Imaging."},{"key":"B20","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.ahj.2012.04.015","article-title":"Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the transthyretin amyloidosis cardiac study (TRACS).","volume":"164","author":"Ruberg","year":"2012","journal-title":"Am Heart J."},{"key":"B21","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s00392-017-1167-1","article-title":"Predictors of survival stratification in patients with wild-type cardiac amyloidosis.","volume":"107","author":"Siepen","year":"2018","journal-title":"Clin Res Cardiol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement.","volume":"38","author":"Castano","year":"2017","journal-title":"Eur Heart J."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1002\/ejhf.1756","article-title":"Light-chain and transthyretin cardiac amyloidosis in severe aortic stenosis: prevalence, screening possibilities, and outcome.","volume":"22","author":"Nitsche","year":"2020","journal-title":"Eur J Heart Fail."},{"key":"B24","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ejim.2020.05.015","article-title":"Safety and tolerability of neurohormonal antagonism in cardiac amyloidosis.","volume":"80","author":"Aimo","year":"2020","journal-title":"Eur J Intern Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3109\/13506129.2012.761967","article-title":"Evaluation of patients with cardiac amyloidosis using echocardiography, ECG and right heart catheterization.","volume":"20","author":"Granstam","year":"2013","journal-title":"Amyloid."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1002\/ejhf.899","article-title":"Inotropic myocardial reserve deficiency is the predominant feature of exercise haemodynamics in cardiac amyloidosis.","volume":"19","author":"Clemmensen","year":"2017","journal-title":"Eur J Heart Fail."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.echo.2008.11.029","article-title":"Echocardiographic assessment of valve stenosis: eae\/ase recommendations for clinical practice.","volume":"22","author":"Baumgartner","year":"2009","journal-title":"J Am Soc Echocardiography."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1093\/eurheartj\/ehaa131","article-title":"Untangling the physiology of transthyretin cardiac amyloidosis by leveraging echocardiographically derived pressure\u2013volume indices.","volume":"41","author":"Rosenblum","year":"2020","journal-title":"Eur Heart J."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1016\/j.jacc.2019.09.056","article-title":"Aortic stenosis and cardiac amyloidosis: JACC review topic of the week.","volume":"74","author":"Ternacle","year":"2019","journal-title":"J Am College Cardiol."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1085824\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T04:52:11Z","timestamp":1674795131000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1085824\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,27]]},"references-count":29,"alternative-id":["10.3389\/fcvm.2023.1085824"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2023.1085824","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,27]]},"article-number":"1085824"}}